Other analysts have also issued research reports about the company. UBS Group set a GBX 1,600 ($20.71) price target on GlaxoSmithKline and gave the company a buy rating in a report on Friday, May 25th. Liberum Capital reiterated a buy rating on shares of GlaxoSmithKline in a report on Wednesday, May 16th. Jefferies Financial Group set a GBX 1,650 ($21.36) price target on GlaxoSmithKline and gave the company a buy rating in a report on Monday, May 14th. Berenberg Bank boosted their price target on GlaxoSmithKline from GBX 1,780 ($23.04) to GBX 1,790 ($23.17) and gave the company a buy rating in a report on Wednesday, April 25th. Finally, Goldman Sachs Group set a GBX 1,900 ($24.60) price target on GlaxoSmithKline and gave the company a buy rating in a report on Friday, June 29th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of GBX 1,541.74 ($19.96).
Shares of GlaxoSmithKline opened at GBX 1,575.60 ($20.40) on Tuesday, according to MarketBeat Ratings. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($15.99) and a 52-week high of GBX 1,724.50 ($22.32).
The firm also recently declared a dividend, which will be paid on Thursday, October 11th. Stockholders of record on Thursday, August 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date is Thursday, August 9th.
In other GlaxoSmithKline news, insider Philip R. Hampton purchased 2,810 shares of GlaxoSmithKline stock in a transaction dated Wednesday, July 25th. The shares were acquired at an average cost of GBX 1,557 ($20.16) per share, with a total value of £43,751.70 ($56,636.50). Also, insider David Redfern sold 1,925 shares of the company’s stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of GBX 1,575 ($20.39), for a total value of £30,318.75 ($39,247.57).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.